NI202000056A - Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro - Google Patents
Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puroInfo
- Publication number
- NI202000056A NI202000056A NI202000056A NI202000056A NI202000056A NI 202000056 A NI202000056 A NI 202000056A NI 202000056 A NI202000056 A NI 202000056A NI 202000056 A NI202000056 A NI 202000056A NI 202000056 A NI202000056 A NI 202000056A
- Authority
- NI
- Nicaragua
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202000056A true NI202000056A (es) | 2021-01-11 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202000056A NI202000056A (es) | 2018-02-23 | 2020-08-21 | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro |
Country Status (19)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313368A (en) * | 2018-02-23 | 2024-08-01 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| WO2021055124A1 (en) * | 2019-09-20 | 2021-03-25 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2318960A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| DE60330909D1 (de) * | 2003-08-08 | 2010-02-25 | Biovail Lab Int Srl | Tablette mit modifizierter freisetzung von bupropion hydrochlorid |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| IL313368A (en) * | 2018-02-23 | 2024-08-01 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Application Discontinuation
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko active Pending
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3092076A1 (en) | 2019-08-29 |
| KR20240091043A (ko) | 2024-06-21 |
| IL276871A (en) | 2020-10-29 |
| EP3755312A1 (en) | 2020-12-30 |
| BR112020017179A2 (pt) | 2020-12-22 |
| CR20200415A (es) | 2021-02-03 |
| ECSP20060179A (es) | 2020-12-31 |
| NZ767378A (en) | 2024-03-22 |
| MX2023009281A (es) | 2023-08-17 |
| MY202993A (en) | 2024-05-31 |
| JP2024075655A (ja) | 2024-06-04 |
| AU2022204521A1 (en) | 2022-07-21 |
| CL2020002166A1 (es) | 2020-10-23 |
| MA51914A (fr) | 2020-12-30 |
| SG11202008056SA (en) | 2020-09-29 |
| IL276871B1 (en) | 2024-07-01 |
| KR20230075531A (ko) | 2023-05-31 |
| JP2021513998A (ja) | 2021-06-03 |
| AU2019223187A1 (en) | 2020-09-17 |
| WO2019165379A1 (en) | 2019-08-29 |
| AU2022204521B2 (en) | 2024-09-05 |
| AU2024205858A1 (en) | 2024-09-05 |
| IL313368A (en) | 2024-08-01 |
| EP3755312A4 (en) | 2022-03-16 |
| JP2022153638A (ja) | 2022-10-12 |
| MX2020008704A (es) | 2020-12-07 |
| CN112087999A (zh) | 2020-12-15 |
| KR20210003091A (ko) | 2021-01-11 |
| AU2019223187B2 (en) | 2022-07-28 |
| PE20211752A1 (es) | 2021-09-06 |
| IL276871B2 (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000056A (es) | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro | |
| CL2019001293A1 (es) | Agentes, usos y métodos para el tratamiento de la sinucleinopatía. | |
| MX2016010235A (es) | Composicion farmaceutica que comprende eritrocitos que encapsulan una enzima dependiente de fosfato de piridoxal (plp) y su cofactor. | |
| BR112015006441A2 (pt) | indicação e ativação de conjuntos de parâmetros para codificação de vídeo | |
| MX2022015115A (es) | Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos. | |
| GT201600137A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| UY36703A (es) | Composiciones y métodos para la administración de un polinucleótido en una planta | |
| MX2023009631A (es) | Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi. | |
| CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| BR112018074655A2 (pt) | formulação injetável de fosnetupitant e método de fabricação de uma formulação | |
| EP3854799A4 (en) | CYCLIC DINUCLEOTIDE ANALOG, PHARMACEUTICAL COMPOSITION AND USE | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| MX370884B (es) | Derivados de catecolamina enriquecidos con deuterio asimétrico posición-específico y medicamentos que comprenden los compuestos. | |
| CL2018002200A1 (es) | Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas. | |
| BR112017013532A2 (pt) | composição de resina | |
| BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| MY198201A (en) | A Combination Medicament Comprising Phenylephrine And Paracetamol | |
| ECSP22030119A (es) | Formas de dosificación y métodos para bupropión enantioméricamente enriquecido o puro | |
| MX2020013385A (es) | Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion. | |
| AR097590A1 (es) | Métodos para tratar el síndrome del x frágil y trastornos relacionados | |
| MX2018010367A (es) | Titulacion de cebranopadol. | |
| BR112021011755A8 (pt) | Método para fornecer um benefício de tratamento bucal com o uso de um composto de cálcio de baixa solubilidade e fluoreto |